MorphoSys AG: MorphoSys expects top-line results from the Phase 3 study of pelabresib in myelofibrosis in early 2024
EQS-News: MorphoSys AG / Key word(s): Conference
MorphoSys AG: MorphoSys expects top-line results from the phase 3 study
Pelabresib in myelofibrosis in early 2024
09.01.2023 / 07:01 CET/EST
The issuer / publisher is responsible for the content of the notification.
media release
Planegg/Munich, January 9, 2023
MorphoSys expects top-line results from phase 3 study with pelabresib
Myelofibrosis Anfang 2024
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that the
Top-line results expected from ongoing Phase 3 MANIFEST-2 study
Will be available in early 2024. MANIFEST-2 is a global,
randomized, double-blind phase 3 clinical trial evaluating the combination
of pelabresib, an investigational drug
BET inhibitor, in combination with ruxolitinib as first-line treatment
studied patients with myelofibrosis. The company had previously
informed that these data are expected in the first half of 2024
would. dr Jean-Paul Kress, Chief Executive Officer of MorphoSys, will
Wednesday, January 11, 2023 at 5:15 p.m. Pacific Time at 41st JP
Morgan Healthcare Conference in San Francisco for more news
Pelabresib and MorphoSys’s oncology pipeline.
“Patients with myelofibrosis respond to current first-line therapy
not sufficient and only for a limited time. The most recently featured
Phase 2 data suggests that pelabresib may have the potential to
to improve the current standard of care, which increases our confidence in the
Phase 3 MANIFEST-2 study strengthened,” says Dr. Jean-Paul Kress. “We are pleased
We look forward to sharing more news about pelabresib and our other clinical
programs during the JP Morgan Healthcare Conference.”
The live webcast of the presentation can be viewed on the MorphoSys website at
https://www.morphosys.com/en/investors. The presentation
and a replay of the webcast will also be available on
MorphoSys provided.
About MorphoSys
At MorphoSys we have a clear mission: we want people with cancer
enable a better and longer life. As a global, commercial
focused biopharmaceutical company, we use cutting-edge science and
Technologies to discover, develop and
to make available to patients. MorphoSys is headquartered in
Planegg, Germany and conducts its business in the USA from Boston,
Massachusetts. Visit www.morphosys.com for more information. consequences
us on LinkedIn and Twitter.
About Pelabresib
Pelabresib (CPI-0610) is a selective small molecule drug in the
Developmental phase characterized by inhibition of the function of BET proteins (BET
– bromodomain and extra terminal domain) promote anti-tumor activity
to increase the expression of abnormally expressed genes in cancer
to decrease. Pelabresib is currently used to treat myelofibrosis
examined and has not yet been examined by a regulatory authority or
authorized.
About myelofibrosis
Myelofibrosis is a form of chronic leukemia that leads to a
extensive scarring of the bone marrow, reducing the normal
Production of healthy blood cells in the body is disturbed. The result is one
Reduction in red blood cells, leading to weakness and fatigue
may, as well as a reduction in blood platelets, increasing the risk of
Bleeding increased due to poor blood clotting. The myelofibrosis
is often associated with an enlarged spleen, which affects the quality of life
patients significantly affected. It is most common in people over
Diagnosed at the age of 50 and can be diagnosed independently (as primary myelofibrosis)
or as a result of another bone marrow disorder.
About MANIFESTO-2
MANIFEST-2 (NCT04603495) is a global, double-blind, randomized
Phase 3 clinical trial of pelabresib in combination with ruxolitinib
versus placebo plus ruxolitinib in JAK inhibitor-naïve patients
myelofibrosis. The primary endpoint of the study is a reduction in
Spleen volume by at least 35% (SVR35) from baseline at 24
weeks. A key secondary endpoint of the study is improvement
Total Symptom Score (TSS50) by 50% or more vs
Baseline after 24 weeks. Constellation Pharmaceuticals, Inc., a
subsidiary of MorphoSys, is the sponsor of the MANIFEST-2 study.
Forward-Looking Statements
This release contains certain forward-looking statements about the
MorphoSys Group. The forward-looking statements contained herein
reflect MorphoSys’s assessment at the time of this announcement
and involves known and unknown risks and uncertainties
could cause actual results, financial condition and
the liquidity, performance or achievements of MorphoSys or the
Industry results significantly different from those in the forward-looking
Statements expressed or implied are historical or
future results, financial position and liquidity, performance
or deviate from the achievements. Even if the results, the performance, the
Financial position and liquidity of MorphoSys and the development of
Industry in which the company operates with these future-oriented
Statements are consistent, they cannot predict outcomes or
developments in future periods. Among the factors that
deviations can result. On the factors that lead to deviations
may include the fact that MorphoSys’s expectations may be wrong
could, the inherent uncertainties associated with
competitive developments, clinical trials and
product development activities and regulatory approval requirements,
MorphoSys’s dependence on collaborations with third parties that
Assessing the commercial potential of its development programs and
other risks identified in the risk factors in MorphoSys’s annual report
Form 20-F and others filed with the US Securities and Exchange Commission
documents are specified. Given these uncertainties, the reader is
advised not to rely on such forward-looking statements.
These forward-looking statements speak only as of the date of the
publication of this document. MorphoSys expressly disclaims any
undertakes no obligation to comply with any such forward-looking statements contained in this document
update to reflect changed expectations regarding it or changed
Events, conditions or circumstances on which any such statement is based
or which may affect the probability that the actual
results differ from those set forth in the forward-looking statements,
to reflect, unless expressly required to do so by law or
required by regulation.
For more information please contact:
MorphoSys
Media contacts: Thomas Biegi Investor contacts: Dr. Julia
Vice President Tel.: +49 (0)89 Neugebauer Head of Investors
/ 89927 26079 Relations Tel: +49 (0)89 / 899 27 179
[1]thomas.biegi@morphosys.com [1]julia.neugebauer@morphosys.com 1.
1. mailto:julia.neugebauer@morphosys.com
mailto:thomas.biegi@morphosys.
com
Eamonn Nolan Director Tel: +1
617-548-9271
eamonn.nolan@morphosys.com
01/09/2023 CET/CEST Publication of a corporate news/financial message,
transmitted by EQS News – a service of EQS Group AG.
The issuer / publisher is responsible for the content of the notification.
The EQS distribution services include statutory reporting obligations, corporate
News/financial news and press releases.
Media archive at https://eqs-news.com
Language: German
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Deutschland
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-Mail: investors@morphosys.com
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: SDAX, TecDAX
Stock exchanges: Regulated market in Frankfurt (Prime Standard);
Open market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 1529819
End of message EQS News Service
1529819 09.01.2023 CET/CEST
ISIN DE0006632003
AXC0060 2023-01-09/09:05
Copyright dpa-AFX business news GmbH. All rights reserved. Redistribution, republication or permanent storage without the express prior consent of dpa-AFX is not permitted.